Skip to main content

Adam P. Samansky

Member

[email protected]

+1.617.348.1819

Share:

Adam is an experienced IP litigator who primarily serves life sciences and defense industry clients. He is lead counsel, handling patent and trade secret disputes, in addition to providing strategic counsel on IP portfolio development, licensing and enforcement. Adam has a strong record of success in multiparty, highly contested Hatch-Waxman litigation, in addition to other litigations involving advanced biochemistry, polymers, optics, manufacturing processes, and other cutting edge technologies. He has tried cases before multiple US district courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and briefed bet-the-company issues before the US Supreme Court.

For pharmaceutical clients, Adam leverages his trial and appellate experience in litigation when advising on new product development, regulatory strategy, Orange Book listing, citizen petition practice, and the settlement of multiparty, highly contested Hatch-Waxman litigation. Adam also advises on due diligence, including reviewing and assessing litigation, regulatory, and competitive strategies.

Adam is an experienced IP litigator who primarily serves life sciences and defense industry clients. He is lead counsel, handling patent and trade secret disputes, in addition to providing strategic counsel on IP portfolio development, licensing and enforcement. Adam has a strong record of success in multiparty, highly contested Hatch-Waxman litigation, in addition to other litigations involving advanced biochemistry, polymers, optics, manufacturing processes, and other cutting edge technologies. He has tried cases before multiple US district courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and briefed bet-the-company issues before the US Supreme Court.

Experience

  • Jazz Pharmaceuticals Ireland, Ltd. v. Teva Pharmaceuticals, Inc., 21-cv-14271, 23-cv-01617, 24-cv-08785.  Lead counsel to Teva Pharmaceuticals, Inc. in consolidated ANDA litigations involving mixed salt formulation of gamma hydroxybutyrate oral solution.
  • Trupanion, Inc. v. Destination Pet, Inc., No. 23-2-18452 (Sup. Ct.King Cty).  Lead counsel to Destination Pet, Inc. in defense of trade secret misappropriation claims and prosecution of counterclaim for abuse of process.
  • Philips Medical Systems (Cleveland), Inc. v. GL Leading, Inc., 1:19-cv-02648 (N.D. Ill.), 24-1182 (7th Cir.) – Lead counsel to Philips in a case brought against domestic and international competitors, inter alia, alleging misappropriation of trade secrets relating to the design and manufacture of X-ray tubes used in commuted tomography.  Obtained sanction of default judgement against China-based companies after successfully defeating serial motions to dismiss and compelling discovery over China State Secrets and Data Protection Law objections.  Obtained permanent injunction with no geographic or temporal limitation, in addition to an award of attorneys’ fees and contempt sanctions against China-based defendants.  Obtained summary dismissal of interlocutory appeal of contempt sanctions, and stay of litigation against U.S.-based defendants in view of pending criminal investigation of related misconduct of U.S. defendants by U.S. Department of Justice.
  • Keter Home and Garden Products, Ltd. v. Five Hole International, LLC, 1:21-cv-01291 (D. Del.) – Lead Counsel to Keter in trade secret and patent inventorship dispute.  Obtained extremely favorable settlement resulting in assignment of disputed patent application.
  • Keter Luxembourg Sarl v. Home Products International – North America, Inc., 1:21-cv-00477 (D. Del.) – Lead counsel to Keter in patent infringement litigation involving design patent covering highly successful line of consumer products.  Obtained favorable early settlement prohibiting continued marketing of accused products in U.S. and other global markets.
  • Horizon Medicines LLC v. Teva Pharmaceuticals USA, Inc., 2:20-cv-08188 (D.N.J.) – Lead Counsel to Teva Pharmaceuticals USA, Inc., in ANDA litigation involving fixed-dose oral combination product. Obtained dismissal with prejudice after briefing case-dispositive claim construction.
  • Evoke Pharma, Inc. v. Teva Pharmaceuticals, Inc., 1:22-cv-02019 (D.N.J.) - Lead Counsel to Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., in ANDA litigation involving metoclopramide nasal spray product.
  • WePower Technologies LLC v. GenerEN, LLC, 7:22-cv-03364 (S.D.N.Y) – Co-lead counsel to WePower in trade secret misappropriation litigation seeking, inter alia, assignment of patent purporting to claim misappropriated energy harvesting technology.
  • Lions Investment & Trading, Inc. v. Republic Floor, LLC, 22-cv-02777 (C.D. Cal.) – Lead counsel to defendant in trademark and unfair competition litigation.  Efficiently obtained favorable negotiated resolution.
  • ClimaCell, Inc. v. Hagit Messer-Yaron, 1:19-cv-11487 (D. Mass.) – Lead counsel to individual defendant in trade secret and breach of contract litigation.  Obtained highly favorable settlement during pendency of motions to dismiss.
  • Rehrig Pacific Co. v. Polymer Logistics (Israel), Ltd., et al., 2:19-cv-04952 (C.D. Cal.) – Lead counsel to Polymer Logistics (Israel) Ltd., defended claims of patent infringement brought by a competitor.  Successfully brought a motion to transfer the action from the U.S. District Court for the Southern District of Georgia to the Central District of California, and also obtained dismissal of willful infringement claims through the strategic use of Rule 12(b)(2) and 12(b)(6) motion practice.
  • Green Cross Corporation v. Shire Human Genetic Therapies, Inc., Appeal No. 17-2071 (Fed. Cir) – Served as appellate counsel to Green Cross Corporation, successfully defeating a motion to dismiss for lack of standing to challenge a final written decision from the Patent Trial and Appeal Board.
  • Kowa Pharmaceuticals America et al v. Amneal Pharmaceuticals, LLC, and related cases – Represented plaintiffs Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. in litigation which involved compound, formulation, and polymorph patents directed toward quinoline-type mevalonolactones (or, pitavastatin calcium) relating to the drug product Livalo®. Presented the plaintiffs' infringement case at 10-day trial, through which plaintiffs prevailed on all issues. Also represented Kowa and Nissan in connection with the Federal Circuit’s affirmance of the district court’s judgment, and was involved in the team’s successful POPR, resulting in a denial of institution of three petitions for inter partes reviews filed by defendants in these cases.
  • Novatrans Group S.A. v. Vital Farms, Inc., et al, 1:18-cv-01012 (D. Del.) – Lead counsel, representing Novatrans Group S.A. (“Novatrans”).  Brought a claim for declaratory judgment to require assignment of certain patent rights and a claim under the Federal Defend Trade Secrets Act in the District of Delaware, while simultaneously defending a breach of contract claim against Novatrans in the Western District of Texas. These cases involved duelling claims of inventorship of a system to determine the fertility status and gender of an avian egg before hatching. Obtained a settlement resulting in publicly recorded assignments of the contested patent application to Novatrans.
  • CAI Software , LLC v. Multimetco, Inc., 1:19-cv-00540 (D.R.I.) – Lead counsel to plaintiff in trade secret misappropriation and copyright infringement litigation. 
  • M&C Innovations, LLC v. Igloo Products Corp., 4:17-cv-02372 (W.D. Tex.) – Served as lead counsel, defending Igloo from allegations of patent infringement and unfair competition involving one of his client’s most significant product lines. 
  • Wireless Monitoring Systems, LLC v. SimpliSafe, Inc., 2:16-cv-1241 (E.D. Tex) – Successfully defended claim of patent infringement by non-practicing entity.
  • Tangelo IP, LLC v. TigerDirect, Inc., 2:15-cv-00771 (E.D. Tex.) – Successfully defended claim of patent infringement by non-practicing entity, after being engaged by supplier of accused technology.  Obtained favorable outcome for supplier all end-users of accused technology.
  • Inline Plastics Corp. v. EasyPak, LLC, 799 F.3d 1364 (Fed. Cir. 2015) – Served as principal appellate counsel, arguing for reversal and remand on case-dispositive claim construction. Previously obtained dismissal of invalidity counterclaims and entry of judgment on infringement to permit expedited appeal. Inline achieved highly-favorable settlement on remand.
  • MKS Instruments v. Emphysys, C.A. No. 12-1858-BLS (Ma. Super. Ct.) – Served as lead counsel, defending against claims of trade secret misappropriation related to advanced semiconductor manufacturing technology.  The case settled very favorably after a positive summary judgment hearing.
  • MeadWestvaco v. Rexam, Appeal No. 12-1518 (Fed. Cir.) – Served as principal appellate counsel, and subsequently represented the plaintiff-appellee on remand to the Eastern District of Virginia. The appeal dealt with matters of claim construction, summary judgment decision of non-obviousness, denial of summary judgment of indefiniteness, and bench finding of infringement.
  • Dallakian v. IPG Photonics, 3:14-cv-11863-TSH (D. Mass.) – Served as lead counsel, successfully defending against claims for correction of inventorship and trade secret misappropriation. Plaintiff voluntarily dismissed the complaint after defendant secured expedited discovery and an early summary judgment motion.
  • VLP Watertown L.P. v. Tristate Breeders Cooperative d/b/a/ Accelerated Genetics, 1:07-cv-11487-GAO (D. Mass.) – Represented VLP in litigation of trade secret misappropriation claims involving a cell processing method shown to improve fertility and induce statistically significant female gender bias in dairy herds. Obtained jury verdict of trade secret misappropriation and multimillion-dollar judgment in our client’s favor.
  • Mitsubishi Chem. Co. v. Barr Labs., Inc., 718 F. Supp. 2d 382 (S.D.N.Y. 2010), aff’d, 435 Fed. Appx. 927 (Fed. Cir. Aug. 2, 2011) – Served as trial and appellate counsel to pioneer pharmaceutical company in a Hatch-Waxman patent infringement action.
  • Takeda Chem. Indus., Ltd. v. Mylan Labs. Inc., 417 F. Supp. 2d 341 (S.D.N.Y. 2006) – Served as trial and appellate counsel to pioneer pharmaceutical company in Hatch-Waxman patent infringement action.
Read less

viewpoints

Trade Secret Thieves, Beware! The DTSA Can Reach You and Your Sales Around the Globe.

July 30, 2024 | Blog | By Michael Renaud, Brad M Scheller, Adam Samansky, Laura Petrasky

This month the Seventh Circuit in Motorola Sols., Inc. v. Hytera Commc’ns Corp. Ltd. upheld the Northern District of Illinois in finding that the Defend Trade Secrets Act (DTSA) has extraterritorial reach. Companies can seek relief when misappropriation occurs abroad and for the sales lost abroad when an act in furtherance of the trade secret misappropriation occurs in the United States.

Read more
Intellectual Property Viewpoints Thumbnail

Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out

April 25, 2024 | Blog | By Joe Rutkowski, Peter Cuomo, Thomas Wintner, Adam Samansky, Alex Trimble, PhD

In a precedential opinion issued on April 11, 2024 in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Nos. 22-2153, 23-1952, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision holding claims directed to polymorphic form “β” of rifaximin invalid as obvious. 

Read more

How Your Trade Secret Could Help to Defend Against Claims of Patent Infringement

February 1, 2024 | Blog | By Adam Samansky, Peter Cuomo, Nicholas Armington, Stephen Chen

Read more

Supreme Court Unanimously Affirms Amgen Repatha® Antibody Patents Invalid for Lack of Enablement

May 25, 2023 | Blog | By Joe Rutkowski, Peter Cuomo, Thomas Wintner, Adam Samansky, Terri Shieh-Newton

Read more

Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book

March 6, 2023 | Blog | By Peter Cuomo, Adam Samansky, Peter McFadden

On February 24, 2023, the U.S. Court of Appeals for the Federal Circuit, in Jazz Pharmaceuticals, Inc., v. Avadel CNS Pharmaceuticals, LLC, Case No. 23-1186, affirmed a decision from the District Court of Delaware directing Jazz Pharmaceuticals, Inc. (“Jazz”) to delist U.S. Patent No. 8,731,963 (the “’963 patent”) from the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations publication (the “Orange Book”). The district court held, and the Federal Circuit affirmed, that the ’963 patent, which covers Risk Evaluation and Mitigation Strategies (“REMS”) for the narcolepsy drug Xyrem®, failed to claim a drug or method of use, and was thus improperly listed.

Read more

On January 9, 2023, the U.S. Court of Appeals for the Federal Circuit in In re Stingray IP Solutions, LLC, No. 23-102 granted a writ of mandamus, vacating a decision of the Eastern District Court of Texas which had transferred a patent infringement suit filed against foreign defendants to the Central District of California based on defendants’ post-suit consent to jurisdiction there.

Read more

On December 19, 2022, U.S. Magistrate Judge Robert W. Lehrburger of the Southern District of New York recommended denying a motion to dismiss claims of willful infringement of eight patents asserted in a Second Amended Complaint (“SAC”). The recommendation finds (1) that pleading willful infringement does not require allegations of egregious infringing conduct and (2) that requisite knowledge of the asserted patents and alleged infringement could be satisfied by the filing of the Original Complaint along with plaintiff’s email (“pre-SAC email”) informing the defendants of additional alleged infringement of two patents prior to filing the SAC.

Read more

On October 5, 2022, U.S. Magistrate Judge Roy S. Payne of the Eastern District of Texas recommended denying-in-part a motion for summary judgment of no willful infringement, holding that requisite knowledge of the asserted patent and alleged infringement of that patent could be satisfied by notice of the lawsuit before the moving defendant was added as a party.

Read more

An Emerging Split on the Applicability of the Inevitable Disclosure Doctrine Under the DTSA

October 10, 2022 | Blog | By Oliver Ennis, Nicholas Armington, Adam Samansky

Federal courts remain split on whether the Defend Trade Secrets Act (DTSA) allows for trade secret misappropriation claims brought under a theory of inevitable disclosure. Given this current patchwork of treatment of inevitable disclosure claims across the nation, owners of trade secrets and litigators of trade secret claims should continue to stay up to date on the treatment of this issue in the jurisdictions in which they practice.

Read more

On July 12, 2022, U.S. District Judge Alan D. Albright of the Western District of Texas denied alleged infringer Lenovo’s motion to dismiss ACQIS’s willful and indirect infringement and enhanced damages claims, holding that patent owners need not allege egregious infringing behavior to assert a claim of willful infringement.

Read more
Read less

News & Press

Press Release Thumbnail Mintz

Mintz is pleased to announce that 31 attorneys have been named Massachusetts Super Lawyers and 35 attorneys have been named Massachusetts Rising Stars for 2024.

Press Release Thumbnail Mintz

187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.

Press Release Thumbnail Mintz

BOSTON – Nine Intellectual Property attorneys from Mintz have been recognized in the 2024 edition of the Intellectual Asset Management (IAM) Strategy 300 Global Leaders Guide.

Press Release Thumbnail Mintz

Mintz is pleased to announce that 32 attorneys have been named Massachusetts Super Lawyers and 27 attorneys have been named Massachusetts Rising Stars for 2023.

Press Release Thumbnail Mintz

Mintz is pleased to announce that Member and Chair of the firm’s Intellectual Property Division Michael Renaud and Members Matthew GalicaFrank GerratanaMarguerite McConiheMichael NewmanAdam RizkAdam SamanskyDaniel Weinger, and James Wodarski have been named to the 2023 IAM Strategy 300: The World’s Leading IP Strategists list.

Press Release Thumbnail Mintz

Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.

Press Release Thumbnail Mintz

BOSTON – Mintz is pleased to announce that it has become an official sponsor of the Pan-Mass Challenge (PMC).

News Thumbnail Mintz

Member Adam Samansky spoke to The Boston Business Journal about the FTC's proposal to ban noncompete agreements.

News Thumbnail Mintz

Members Adam Samansky and Peter Cuomo spoke to Managing IP  on the implications that a pending case in the Court of Appeals for the Federal Circuit could have on litigation and prosecution strategies for life sciences companies.

News Thumbnail Mintz

Mintz Member Adam Samansky and Associates Nicholas Armington and Oliver Ennis co-authored an article re-published in Law360 exploring the split amongst federal courts on the Defend Trade Secrets Act.

Press Release Thumbnail Mintz

35 Mintz attorneys have been named Massachusetts Super Lawyers and 25 Mintz attorneys have been named Massachusetts Rising Stars for 2022.

Press Release Thumbnail Mintz

Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.

News Thumbnail Mintz
Mintz Members Peter Cuomo and Adam Samansky and Associate Joseph Rutkowski were quoted in an article published by Law360 on the potential implications of the Federal Circuit’s recent ruling in Celgene Corp. v. Mylan Pharmaceuticals Inc., which cemented a prior decision in Valeant v. Mylan holding that patent suits against generic drugmakers must be filed where the company is incorporated or where it performed actions related to its Abbreviated New Drug Application.
News Thumbnail Mintz
Mintz Members Peter Cuomo and Adam Samansky co-authored an article published by IAM examining the U.S. Supreme Court’s decision to deny a petition for certiorari in Eli Lilly and Co. v Hospira, Inc., upholding the infringement of Eli Lilly’s chemotherapy drug Alimta (pemetrexed), and what the development means for the doctrine of equivalents and for patent application amendments.
News Thumbnail Mintz
Law360 covered developments in a trade secret lawsuit involving X-ray tubes brought on by Mintz client Philips Medical Systems, Inc. against Chinese companies Kunshan GuoLi Electronic Technology Co. Ltd. and its subsidiary, Kunshan Yiyuan Medical Technology Co. Ltd.
In this article published by Law360, Mintz Members Adam Samansky and Peter Cuomo commented on lingering questions related to the America Invents Act's estoppel provision, which prevents challengers from arguing in court that a patent is invalid on grounds that were raised — or reasonably could have been raised — during inter partes review at the Patent Trial and Appeal Board.
Mintz has secured a string of substantial victories in Hatch-Waxman litigation for innovative drug manufacturers Kowa Pharmaceutical Co., Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Industries Ltd.
Press Release Thumbnail Mintz
Best Lawyers named 85 Mintz attorneys to its 2018 list of The Best Lawyers in America. In addition, Mintz attorneys Matthew J. Gardella and Samuel M. Tony Starr were named “Lawyer of the Year” in their respective practice areas.
Mintz announced a pair of victories before the Patent Trial and Appeal Board on behalf of SL Corporation and Hyundai Motor America, Inc. against Adaptive Headlamp Technologies, Inc.
Fifty-three Mintz attorneys have been named Massachusetts Super Lawyers for 2016 and thirty-one have been named Massachusetts Rising Stars. The findings will be published in the November 2016 issue of Boston Magazine and in a stand-alone magazine, New England Super Lawyers. 
Read less

Events & Speaking

Panelist
Oct
8
2024

Hatch-Waxman and BPCIA Conference

American Conference Institute

Virtual

Conference Reference Image
Panelist
Panelist
Mar
21
2024

IP in the Digital Age: Trends and Transformations

Boston Bar Association IP Year In Review Conference

Event Reference Image
Speaker
Mar
22
2021

IPBC Connect 2021

IAM

Virtual Event

Conference Reference Image
Speaker
Aug
4
2020
Webinar Reference Image
Panelist
Apr
7
2019

BPIP 7th Annual Conference

Best Practices in Intellectual Property

Sheraton Tel Aviv Tel Aviv, Israel

Moderator
Jun
28
2018

Data Protection at the Intersection of Trade Secrets and Cybersecurity

Boston Patent Law Association

Mintz Levin One Financial Center Boston, MA

Speaker
Apr
30
2018

AIPPI-Israel’s 3rd Annual International Convention on the Economy of Innovation

AIPPI-Israel

David Intercontinental Hotel 12, Kaufman Street Tel Aviv, Israel

Speaker
Mar
11
2018

BPIP 6th Annual Conference

Best Practices in Intellectual Property

Sheraton Tel Aviv Tel Aviv, Israel

Mar
26
2017

Life Sciences Breakfast

GKH Law Offices

Tel Aviv

Speaker
Speaker
Sep
9
2015

2015 U.S. Supreme Court and Federal Circuit Year in Review

Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.

One Azrieli Center, Round Building, Tel Aviv, Israel

Speaker
May
11
2015

IP Best Practices Conference 2015

Intellectual Property Resources

Tel Aviv, Israel

Read less

Adam is an experienced IP litigator who primarily serves life sciences and defense industry clients. He is lead counsel, handling patent and trade secret disputes, in addition to providing strategic counsel on IP portfolio development, licensing and enforcement. Adam has a strong record of success in multiparty, highly contested Hatch-Waxman litigation, in addition to other litigations involving advanced biochemistry, polymers, optics, manufacturing processes, and other cutting edge technologies. He has tried cases before multiple US district courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and briefed bet-the-company issues before the US Supreme Court.

Recognition & Awards

  • Best Lawyers in America: Intellectual Property Litigation (2018 - 2025)

  • Named to IAM Strategy 300: Global Leaders (2024)

  • Included on the Massachusetts Super Lawyers - Intellectual Property Litigation list (2021 – 2023)

  • Included on the Massachusetts Super Lawyers: Rising Star - Intellectual Property Litigation list (2013 – 2018)

Read less

Adam is an experienced IP litigator who primarily serves life sciences and defense industry clients. He is lead counsel, handling patent and trade secret disputes, in addition to providing strategic counsel on IP portfolio development, licensing and enforcement. Adam has a strong record of success in multiparty, highly contested Hatch-Waxman litigation, in addition to other litigations involving advanced biochemistry, polymers, optics, manufacturing processes, and other cutting edge technologies. He has tried cases before multiple US district courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and briefed bet-the-company issues before the US Supreme Court.

Involvement

  • Member, Boston Bar Association
  • Member, American Intellectual Property Law Association
  • Member, Boston Intellectual Property Law Association, Co-Chair Trade Secrets Committee
  • Member, Federal Circuit Bar Association
Read less